My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
March 2012
Education & Resources
Advance Access to JID and CID Manuscripts

To speed publication, both The Journal of Infectious Diseases (JID) and Clinical Infectious Diseases (CID) are now posting the author’s version of most manuscripts upon acceptance. The Advance Access section of each journal displays a mix of “Accepted Manuscripts” (manuscripts  that have undergone peer review but have not yet been copyedited) and “Corrected Proofs” (manuscripts that have been copyedited and formatted for publication). Visit the Advance Access section of JID and CID for more information, including how to cite Advance Access articles.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
EIN Update: A Complex Case of Multidrug Resistant P. aeruginosa
IDSA, SHEA, PIDS Outline National Approach to Antimicrobial Stewardship
C. difficile Infections Growing Threat Across Medical Settings
Drug Approvals, Recalls, Adverse Events Update
Global ID
Highlights from CROI 2012 Conference
New Combo Drug Trial Has Potential to Transform TB Treatment
Global Health Community Applauds Nomination of Jim Yong Kim, MD, PhD, for World Bank
Policy and Advocacy
Patient-Centered Outcomes Research Agenda Should Include ID
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
Advance Access to JID and CID Manuscripts
New Pediatric ID Journal Now Available
Top Stories
From the President: What’s on Tap for IDWeek 2012, Oct. 17-21
New Guideline for Acute Bacterial Rhinosinusitis Now Available
IDSA Proposes New Pathway for Antibiotic Approval,Action from Members Needed
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.